Found: 52
Select item for more details and to access through your institution.
Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA‐MM subgroup analysis.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 11, p. E423, doi. 10.1002/ajh.26319
- By:
- Publication type:
- Article
Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real‐world: The retrospective IMAGE study.
- Published in:
- European Journal of Haematology, 2024, v. 113, n. 3, p. 290, doi. 10.1111/ejh.14225
- By:
- Publication type:
- Article
Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia.
- Published in:
- European Journal of Haematology, 2017, v. 98, n. 4, p. 363, doi. 10.1111/ejh.12836
- By:
- Publication type:
- Article
Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database.
- Published in:
- Vaccines, 2020, v. 8, n. 4, p. 722, doi. 10.3390/vaccines8040722
- By:
- Publication type:
- Article
Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2023, v. 23, n. 5, p. e240, doi. 10.1016/j.clml.2023.02.010
- By:
- Publication type:
- Article
Corrigendum to "OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT" [Clinical Lymphoma Myeloma and Leukemia 21 S2 (2021) S3-S4]
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2022, v. 22, n. 6, p. 425, doi. 10.1016/j.clml.2022.03.010
- By:
- Publication type:
- Article
P-221: Evolution of Dara-based regimen use along treatment lines from 2016 to 2019: a real-life study based on the French national claim database.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S161, doi. 10.1016/S2152-2650(21)02348-X
- By:
- Publication type:
- Article
OAB-016: Treatment pathways for patients with multiple myeloma: a real-life study based on the French National Claim database from 2014 to 2019.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S10, doi. 10.1016/S2152-2650(21)02090-5
- By:
- Publication type:
- Article
OAB-005: Update of safety and efficacy of Isatuximab short-duration fixed-volume infusion plus Bortezomib, Lenalidomide, and Dexamethasone combined therapy for NDMM ineligible/with no immediate intent for ASCT.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S3, doi. 10.1016/S2152-2650(21)02079-6
- By:
- Publication type:
- Article
OAB-001: Overall survival and progression-free survival by treatment duration with Daratumumab + Lenalidomide/Dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: phase 3 MAIA study.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S1, doi. 10.1016/S2152-2650(21)02075-9
- By:
- Publication type:
- Article
MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S424, doi. 10.1016/S2152-2650(21)01950-9
- By:
- Publication type:
- Article
MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S423, doi. 10.1016/S2152-2650(21)01948-0
- By:
- Publication type:
- Article
Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S252, doi. 10.1016/S2152-2650(21)01581-0
- By:
- Publication type:
- Article
Poster: MM-130: Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S250, doi. 10.1016/S2152-2650(21)01572-X
- By:
- Publication type:
- Article
MIROIR: 4-Year Interim Analysis of a Multicenter, Non-Interventional Study in France of Pomalidomide in Relapsed or Refractory Multiple Myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e253, doi. 10.1016/j.clml.2019.09.419
- By:
- Publication type:
- Article
A Prospective Phase II of Daratumumab in Previously Treated Systemic Light-Chain (AL) Amyloidosis: Updated Results.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e40, doi. 10.1016/j.clml.2019.09.061
- By:
- Publication type:
- Article
Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: An Open-label, Multicenter Phase 2 Study (PLEIADES).
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e16, doi. 10.1016/j.clml.2019.09.023
- By:
- Publication type:
- Article
Daratumumab Plus Bortezomib, Thalidomide, and Dexamethasone (D-VTd) in Transplant-eligible Newly Diagnosed Multiple Myeloma (NDMM): Subgroup Analysis of High-risk Patients (Pts) in CASSIOPEIA.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e2, doi. 10.1016/j.clml.2019.09.004
- By:
- Publication type:
- Article
Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 4, p. 1576, doi. 10.1007/s12325-024-02797-x
- By:
- Publication type:
- Article
Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2024, v. 41, n. 2, p. 696, doi. 10.1007/s12325-023-02738-0
- By:
- Publication type:
- Article
Comparative Efficacy of Teclistamab Versus Current Treatments in Real-World Clinical Practice in the Prospective LocoMMotion Study in Patients with Triple-Class-Exposed Relapsed and/or Refractory Multiple Myeloma.
- Published in:
- Advances in Therapy, 2023, v. 40, n. 5, p. 2412, doi. 10.1007/s12325-023-02480-7
- By:
- Publication type:
- Article
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.
- Published in:
- Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00803-z
- By:
- Publication type:
- Article
Dynamic monitoring of myeloma minimal residual disease with targeted mass spectrometry.
- Published in:
- 2023
- By:
- Publication type:
- Letter
A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab.
- Published in:
- 2021
- By:
- Publication type:
- Letter to the Editor
Une cause inhabituelle d'elliptocytose.
- Published in:
- Annales de Biologie Clinique, 2016, v. 74, n. 6, p. 704, doi. 10.1684/abc.2016.1191
- By:
- Publication type:
- Article
Real‐life effectiveness of carfilzomib in patients with relapsed multiple myeloma receiving treatment in the context of early access: The CARMYN study.
- Published in:
- EJHaem, 2024, v. 5, n. 1, p. 55, doi. 10.1002/jha2.828
- By:
- Publication type:
- Article
Revised international staging system allocation in the ICARIA‐MM study: Practical challenges and impact on outcome.
- Published in:
- EJHaem, 2022, v. 3, n. 1, p. 168, doi. 10.1002/jha2.328
- By:
- Publication type:
- Article
Lactic acidosis and hypoglycemia as markers of disease progression of multiple myeloma: A case report.
- Published in:
- EJHaem, 2021, v. 2, n. 3, p. 539, doi. 10.1002/jha2.176
- By:
- Publication type:
- Article
When dystrophic plasma cells do not recognize themselves in the mirror.
- Published in:
- EJHaem, 2020, v. 1, n. 2, p. 408, doi. 10.1002/jha2.100
- By:
- Publication type:
- Article
Central nervous system relapse in patients over 80 years with diffuse large B‐cell lymphoma: an analysis of two LYSA studies.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 3, p. 539, doi. 10.1002/cam4.1139
- By:
- Publication type:
- Article
Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 12, p. 2288, doi. 10.1002/cncr.34211
- By:
- Publication type:
- Article
Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 6, p. 1103, doi. 10.1111/bjh.18772
- By:
- Publication type:
- Article
Lenalidomide maintenance fails to overcome the unfavourable prognosis of low NK‐cell counts in rituximab–chemotherapy responsive elderly DLBCL patients: A LYSA group study.
- Published in:
- British Journal of Haematology, 2023, v. 201, n. 2, p. 256, doi. 10.1111/bjh.18642
- By:
- Publication type:
- Article
Double‐hit multiple myeloma with atypical "faggot" cells.
- Published in:
- British Journal of Haematology, 2022, v. 196, n. 3, p. 462, doi. 10.1111/bjh.17876
- By:
- Publication type:
- Article
Subgroup analysis of ICARIA‐MM study in relapsed/refractory multiple myeloma patients with high‐risk cytogenetics.
- Published in:
- British Journal of Haematology, 2021, v. 194, n. 1, p. 120, doi. 10.1111/bjh.17499
- By:
- Publication type:
- Article
Multiple myeloma with hungry plasma cells.
- Published in:
- British Journal of Haematology, 2021, v. 193, n. 3, p. 443, doi. 10.1111/bjh.17299
- By:
- Publication type:
- Article
Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study.
- Published in:
- British Journal of Haematology, 2021, v. 192, n. 5, p. 869, doi. 10.1111/bjh.16980
- By:
- Publication type:
- Article
Lenalidomide maintenance for diffuse large B‐cell lymphoma patients responding to R‐CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.
- Published in:
- British Journal of Haematology, 2020, v. 189, n. 1, p. 84, doi. 10.1111/bjh.16300
- By:
- Publication type:
- Article
Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014‐04 (Etoile du Nord) trial.
- Published in:
- British Journal of Haematology, 2019, v. 187, n. 3, p. 319, doi. 10.1111/bjh.16059
- By:
- Publication type:
- Article
Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open‐label, phase 1/2 study.
- Published in:
- British Journal of Haematology, 2019, v. 186, n. 3, p. e35, doi. 10.1111/bjh.15879
- By:
- Publication type:
- Article
Tandem haematopoietic stem cell transplantation for High Risk relapsed/refractory Hodgkin Lymphoma: a LYSA study.
- Published in:
- British Journal of Haematology, 2018, v. 181, n. 3, p. 341, doi. 10.1111/bjh.15184
- By:
- Publication type:
- Article
A susceptibility locus for classical Hodgkin lymphoma at 8q24 near <italic>MYC</italic>/<italic>PVT1</italic> predicts patient outcome in two independent cohorts.
- Published in:
- 2018
- By:
- Publication type:
- Abstract
Transformed Waldenström macroglobulinaemia: clinical presentation and outcome. A multi-institutional retrospective study of 77 cases from the French Innovative Leukemia Organization ( FILO).
- Published in:
- British Journal of Haematology, 2017, v. 179, n. 3, p. 439, doi. 10.1111/bjh.14881
- By:
- Publication type:
- Article
Management of a Young Patient With High-risk Multiple Myeloma Complicated by Acquired von Willebrand Syndrome: A Diagnostic and Therapeutic Emergency.
- Published in:
- Plasmatology, 2024, v. 18, p. 1, doi. 10.1177/26348535231222994
- By:
- Publication type:
- Article
Efficacy and Safety Profile of Long-Term Exposure to Lenalidomide in Patients With Recurrent Multiple Myeloma.
- Published in:
- Cancer (0008543X), 2013, v. 119, n. 20, p. 3680, doi. 10.1002/cncr.28274
- By:
- Publication type:
- Article
Les anticorps bispécifiques.
- Published in:
- Hematologie, 2021, v. 27, p. 19, doi. 10.1684/hma.2021.1650
- By:
- Publication type:
- Article
Quelle prise en charge des patients nouvellement diagnostiqués et non éligibles à la greffe ? L'arrivée de l'immunostimulation.
- Published in:
- Hematologie, 2020, p. 12, doi. 10.1684/hma.2020.1545
- By:
- Publication type:
- Article
Multiple Myeloma: Heterogeneous in Every Way.
- Published in:
- Cancers, 2021, v. 13, n. 6, p. 1285, doi. 10.3390/cancers13061285
- By:
- Publication type:
- Article
Risk and Response-Adapted Treatment in Multiple Myeloma.
- Published in:
- Cancers, 2020, v. 12, n. 12, p. 3497, doi. 10.3390/cancers12123497
- By:
- Publication type:
- Article
Serum albumin or body mass index: Which prognostic factor for survival in patients with acute myeloblastic leukaemia?
- Published in:
- 2019
- By:
- Publication type:
- journal article